prikaz prve stranice dokumenta Evaluation of Primary Hyperparathyroidism in Hormone Receptor-Positive Breast Cancer Patients Using [99mTc] Tc-MIBI SPECT/CT and Ultrasound
  Download
PDF 227.81 KB
Other - Conference abstract
Evaluation of Primary Hyperparathyroidism in Hormone Receptor-Positive Breast Cancer Patients Using [99mTc] Tc-MIBI SPECT/CT and Ultrasound
European Journal of Nuclear Medicine and Molecular Imaging, 47 (2020), suppl. 1; S194-S195. https://doi.org/10.1007/s00259-020-04988-4
Punda, M.; Petranović-Ovčariček, P.; Gladić-Nenadić, V.; Šiško-Markoš, I.; Franceschi, M.; Jukić, T.

Citations:
,
Cite this document

Punda, M., Petranović Ovčariček, P., Gladić Nenadić, V., Šiško Markoš, I., Franceschi, M. & Jukić, T. (2020). Evaluation of Primary Hyperparathyroidism in Hormone Receptor-Positive Breast Cancer Patients Using [99mTc] Tc-MIBI SPECT/CT and Ultrasound. European Journal of Nuclear Medicine and Molecular Imaging, 47. (suppl. 1), S194-S195. doi: 10.1007/s00259-020-04988-4

Punda, M., et al. "Evaluation of Primary Hyperparathyroidism in Hormone Receptor-Positive Breast Cancer Patients Using [99mTc] Tc-MIBI SPECT/CT and Ultrasound." European Journal of Nuclear Medicine and Molecular Imaging, vol. 47, no. suppl. 1, 2020, pp. S194-S195. https://doi.org/10.1007/s00259-020-04988-4

Punda, M., P. Petranović Ovčariček, V. Gladić Nenadić, I. Šiško Markoš, M. Franceschi and T. Jukić. "Evaluation of Primary Hyperparathyroidism in Hormone Receptor-Positive Breast Cancer Patients Using [99mTc] Tc-MIBI SPECT/CT and Ultrasound." European Journal of Nuclear Medicine and Molecular Imaging 47, no. suppl. 1 (2020): S194-S195. https://doi.org/10.1007/s00259-020-04988-4

Punda, M., et al. (2020) 'Evaluation of Primary Hyperparathyroidism in Hormone Receptor-Positive Breast Cancer Patients Using [99mTc] Tc-MIBI SPECT/CT and Ultrasound', European Journal of Nuclear Medicine and Molecular Imaging, 47(suppl. 1), pp. S194-S195. doi: 10.1007/s00259-020-04988-4

Punda M, Petranović Ovčariček P, Gladić Nenadić V, Šiško Markoš I, Franceschi M, Jukić T. Evaluation of Primary Hyperparathyroidism in Hormone Receptor-Positive Breast Cancer Patients Using [99mTc] Tc-MIBI SPECT/CT and Ultrasound. European Journal of Nuclear Medicine and Molecular Imaging [Internet]. 2020 [cited 2025 April 03];47(suppl. 1):S194-S195. doi: 10.1007/s00259-020-04988-4

M. Punda, P. Petranović Ovčariček, V. Gladić Nenadić, I. Šiško Markoš, M. Franceschi and T. Jukić, "Evaluation of Primary Hyperparathyroidism in Hormone Receptor-Positive Breast Cancer Patients Using [99mTc] Tc-MIBI SPECT/CT and Ultrasound", European Journal of Nuclear Medicine and Molecular Imaging, vol. 47, no. suppl. 1, pp. S194-S195, 2020. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:220:262212. [Accessed: 03 April 2025]

Please login to the repository to save this object to your list.
Metadata
Title (english)Evaluation of Primary Hyperparathyroidism in Hormone Receptor-Positive Breast Cancer Patients Using [99mTc] Tc-MIBI SPECT/CT and Ultrasound
AuthorM. Punda
AuthorP. Petranović-Ovčariček
AuthorV. Gladić-Nenadić
AuthorI. Šiško-Markoš
AuthorM. Franceschi
AuthorT. Jukić
Author's institution(Sestre milosrdnice University Hospital Center)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Abstract (english)
Breast cancer (BC) patients receiving advanced specific anti-neoplastic treatments are at increased risk for cancer treatment-induced bone loss. The guidelines recommend bone mineral density (BMD) testing by dual-energy X-ray absorptiometry (DXA) and exclusion of secondary causes for low BMD such as primary hyperparathyroidism (PHPT).
Languageenglish
Publication typeOther - Conference abstract
Publication statusPublished
Peer reviewUnknown
Publication versionPublished version
Journal titleEuropean Journal of Nuclear Medicine and Molecular Imaging
Numberingvol. 47, no. suppl. 1, pp. S194-S195
p-ISSN1619-7070
e-ISSN1619-7089
DOIhttps://doi.org/10.1007/s00259-020-04988-4
URN:NBNurn:nbn:hr:220:262212
Publication2020
ConferenceTitle: Annual Congress of the European Association of Nuclear Medicine
Acronym: EANM‘20
Location: Virtual, Germany
Organizer: European Association of Nuclear Medicine
Start date: 2020-10-22
End date: 2020-10-30
Document URLhttps://link.springer.com/article/10.1007/s00259-020-04988-4
Type of resourceText
Access conditionsOpen access
Terms of useLicence In copyright icon
Created on2025-03-19 09:33:31
accessibility

closeAccessibilityrefresh

If you wish to permanently save changes, click on Save, if not - your settings will be reset when you restart the browser.